Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma
Journal of Clinical Investigation · 01.04.2025 · 135 (7)
DOI: 10.1172/jci187024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 30.01.2025. Verfasst von Kang Sun und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine and. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Tumor Microenvironment, Pancreatic Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Metabolic reprogramming shapes the tumor microenvironment (TME) and may lead to immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). Elucidating the impact of pancreatic cancer cell metabolism in the TME is essential to therapeutic interventions. “Immune cold” PDAC is characterized by elevated lactate levels resulting from tumor cell metabolism, abundance of protumor macrophages, and reduced cytotoxic T cells in the TME. Analysis of fluorine-18 fluorodeoxyglucose ( 18 F-FDG) uptake in patients showed that increased global protein lactylation in PDAC correlates with worse clinical outcomes in immunotherapy. Inhibition of lactate production in pancreatic tumors via glycolysis or mutant-KRAS inhibition reshaped the TME, thereby increasing their sensitivity to immune checkpoint blockade (ICB) therapy. In pancreatic tumor cells, lactate induces K63 lactylation of endosulfine α (ENSA-K63la), a crucial step that triggers STAT3/CCL2 signaling. Consequently, elevated CCL2 secreted by tumor cells facilitates tumor-associated macrophage (TAM) recruitment to the TME. High levels of lactate also drive transcriptional reprogramming in TAMs via ENSA-STAT3 signaling, promoting an immunosuppressive environment. Targeting ENSA-K63la or CCL2 enhances the efficacy of ICB therapy in murine and humanized pancreatic tumor models. In conclusion, elevated lactylation reshapes the TME and promotes immunotherapy resistance in PDAC. A therapeutic approach targeting ENSA-K63la or CCL2 has shown promise in sensitizing pancreatic cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine and.
- Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- MOE Joint International Research Laboratory of Pancreatic Diseases, Hangzhou, China.
- Zhejiang Provincial Clinical Research Center for the Study of Hepatobiliary & Pancreatic Diseases, Zhejiang University, Hangzhou, China.
- Cancer Center, Zhejiang University, Hangzhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, K., Zhang, X., Shi, J., Huang, J., Wang, S., Li, X., Lin, H., Zhao, D., Ye, M., Zhang, S., Qiu, L., Yang, M., Liao, C., He, L., Lao, M., Song, J., Lu, N., Ji, Y., Yang, H., …, & Liang, T. (2025). Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Journal of Clinical Investigation, 135(7). https://doi.org/10.1172/jci187024
Vancouver
Sun K, Zhang X, Shi J, Huang J, Wang S, Li X, et al. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Journal of Clinical Investigation. 2025;135(7). doi:10.1172/jci187024
BibTeX
@article{Sun2025,
author = {Sun, Kang and Zhang, Xiaozhen and Shi, Jiatao and Huang, Jinyan and Wang, Sicheng and Li, Xiang and Lin, Haixiang and Zhao, Danyang and Ye, Mao and Zhang, Sirui and Qiu, Li and Yang, Minqi and Liao, Chuyang and He, Lihong and Lao, Mengyi and Song, Jinyuan and Lu, Na and Ji, Yongtao and Yang, Hanshen and Liu, Lingyue and Liu, Xinyuan and Chen, Yan and Yao, Shicheng and Xu, Qianhe and Lin, Jieru and Mao, Yan and Zhou, Jingxing and Zhi, Xiao and Sun, Ke and Lu, Xiongbin and Bai, Xueli and Liang, Tingbo},
title = {Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {7},
doi = {10.1172/jci187024}
}
EUVIMED